Literature DB >> 22094183

Pancreatic dual-source dual-energy CT: is it time to discard unenhanced imaging?

Achille Mileto1, Silvio Mazziotti, Michele Gaeta, Antonio Bottari, Fabrizio Zimbaro, Claudio Giardina, Giorgio Ascenti.   

Abstract

AIM: To compare pancreatic virtual unenhanced (VUE) and true unenhanced (TUE) images and to calculate the potential dose reduction by omitting the conventional unenhanced scan.
MATERIALS AND METHODS: Fifty-one patients with known or suspected pancreatic masses underwent contrast-enhanced computed-tomography (CT) during unenhanced and portal venous phases acquired in single-energy (SE) mode, and pancreatic parenchymal phase acquired in dual-energy (DE) mode. The image quality (IQ) and image noise (IN) of TUE and VUE images were evaluated. The effective dose of a combined DE/SE dual-phase protocol was compared with that of a theoretical standard SE triple-phase protocol. The results were tested for statistical significance using the Cohen's k, the Wilcoxon's signed rank test, and the paired t-test; p-values of less than 0.05 were considered significant.
RESULTS: Mean TUE and VUE IQ were 1.5 ± 0.6 and 1.6 ± 0.6 (k = 0.891), with no significant difference (p > 0.05). Mean TUE and VUE IN were 12.3 ± 1.6 and 10.3 ± 1.5 HU, and resulted significantly different (p < 0.001). Mean effective doses for a combined DE/SE dual-phase protocol and SE triple-phase protocol were 8.9 ± 2.4 mSv (range 4.8-16.2 mSv) and 12.1 ± 3.1 mSv (range 6.4-21.1 mSv). The calculated mean dose reduction achievable by omitting the unenhanced scan was 26.7 ± 9.7% (range 10-46.1; p < 0.001).
CONCLUSION: VUE images are feasible for pancreatic abdominal CT. A combined DE/SE dual-phase protocol permits a significant reduction in dose exposure to patients. Copyright Â
© 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094183     DOI: 10.1016/j.crad.2011.09.004

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  13 in total

Review 1.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.

Authors:  Naveen M Kulkarni; Lorenzo Mannelli; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Olga R Brook; Elizabeth M Hecht; Fay Kastrinos; Zhen Jane Wang; Erik V Soloff; Parag P Tolat; Guillermo Sangster; Jason Fleming; Eric P Tamm; Avinash R Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 2.  Dual energy MDCT assessment of renal lesions: an overview.

Authors:  Achille Mileto; Daniele Marin; Rendon C Nelson; Giorgio Ascenti; Daniel T Boll
Journal:  Eur Radiol       Date:  2013-10-04       Impact factor: 5.315

Review 3.  Advanced imaging techniques for chronic pancreatitis.

Authors:  Anushri Parakh; Temel Tirkes
Journal:  Abdom Radiol (NY)       Date:  2020-05

4.  Pilot study: Evaluation of dual-energy computed tomography measurement strategies for positron emission tomography correlation in pancreatic adenocarcinoma.

Authors:  Jorge Oldan; Miao He; Teresa Wu; Alvin C Silva; Jing Li; J Ross Mitchell; William M Pavlicek; Michael C Roarke; Amy K Hara
Journal:  J Digit Imaging       Date:  2014-12       Impact factor: 4.056

Review 5.  Dual energy CT applications in pancreatic pathologies.

Authors:  Elizabeth George; Jeremy R Wortman; Urvi P Fulwadhva; Jennifer W Uyeda; Aaron D Sodickson
Journal:  Br J Radiol       Date:  2017-09-22       Impact factor: 3.039

6.  Dual-energy CT in early acute pancreatitis: improved detection using iodine quantification.

Authors:  Simon S Martin; Franziska Trapp; Julian L Wichmann; Moritz H Albrecht; Lukas Lenga; James Durden; Christian Booz; Thomas J Vogl; Tommaso D'Angelo
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

Review 7.  Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies.

Authors:  Benjamin M Yeh; Paul F FitzGerald; Peter M Edic; Jack W Lambert; Robert E Colborn; Michael E Marino; Paul M Evans; Jeannette C Roberts; Zhen J Wang; Margaret J Wong; Peter J Bonitatibus
Journal:  Adv Drug Deliv Rev       Date:  2016-09-09       Impact factor: 15.470

8.  Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements.

Authors:  Giorgio Ascenti; Achille Mileto; Bernhard Krauss; Michele Gaeta; Alfredo Blandino; Emanuele Scribano; Nicola Settineri; Silvio Mazziotti
Journal:  Eur Radiol       Date:  2013-03-12       Impact factor: 5.315

9.  Single-portal-phase low-tube-voltage dual-energy CT for short-term follow-up of acute pancreatitis: evaluation of CT severity index, interobserver agreement and radiation dose.

Authors:  Julian L Wichmann; Pawel Majenka; Martin Beeres; Wolfgang Kromen; Boris Schulz; Stefan Wesarg; Ralf W Bauer; J Matthias Kerl; Tatjana Gruber-Rouh; Renate Hammerstingl; Thomas J Vogl; Thomas Lehnert
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

10.  Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using Volume Perfusion CT with 80 kVp.

Authors:  Wolfgang M Thaiss; Ulrike Haberland; Sascha Kaufmann; Daniel Spira; Christoph Thomas; Konstantin Nikolaou; Marius Horger; Alexander W Sauter
Journal:  Eur Radiol       Date:  2015-12-17       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.